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inTRODUCTiOn
Catatonia was described for the first time by Kahlbaum in 1874 (1). It can be defined schematically 
as a motor dysregulation syndrome accompanied with a behavioral component. There are three main 
forms of catatonia: (i) akinetic, (ii) hyperkinetic, and (iii) malignant catatonia (2). These various phe-
notypes of the same syndrome led to a clinical heterogeneousness making the catatonia difficult to 
recognize and diagnose. It seems, however, that certain clinical signs occur with a greater frequency 
in catatonia. Indeed, in a study involving more than 230 catatonic patients, the “staring,” was found 
in more than 80% of cases. Among other frequent signs, were the immobility in 70% of cases, the 
mutism in 60% of patients, and the withdrawal in 50% of them (3). Various specific scales were 
developed to allow a more accurate diagnostic approach to catatonia. The Bush-Francis catatonia 
rating scale is the most commonly used one. It has many advantages: in addition to having a sensitiv-
ity of reaching 100% and a specificity between 75 and 100%, it is fast and easy to use in daily clinical 
practice (4). It is important to note that catatonia is a transnosographic syndrome with various 
underlying psychiatric and somatic causes. Most common somatic causes include epilepsy, systemic 
lupus erythematosus, intermittent porphyria, traumatic brain injury, dementia, encephalopathies 
(autoimmune, paraneoplastic, Hashimoto, etc.) (5). Furthermore, catatonia is found among 10% of 
psychiatric inpatients (6). Under the influence of Kraeplin, catatonia was linked for a long time exclu-
sively with schizophrenia (7). However, recent epidemiological studies showed that schizophrenia 
is found only in 20% of catatonic cases while mood disorders underlie 45% of cases (8). Catatonia 
is also frequent in children and adolescents, particularly in autism spectrum disorders where the 
prevalence varies between 12 and 17% (9). Despite these clinical and epidemiological facts, few data 
exist concerning the exact pathophysiological mechanisms underlying this syndrome. In this paper, 
we will make the synthesis of the existing data concerning the neurocognitive and neurobiological 
mechanisms involved in the akinetic forms of catatonia.
pREFROnTAL pHYSiOLOGY OF EMOTiOnS
Moskowitz considered catatonia as an evolutionary remainder of defense strategies associated with 
intense fear (10). It seems that in front of predators, several survival behaviors have been developed. 
Among them, the most known one was the “fight or flight” strategy. In cases where none of these 
two options was possible, a third strategy called “tonic immobility” (TI) would be set up which 
consists of a tonic suspension of motor activity. This defense strategy is based on the fact that many 
predators are attracted by their prey’s movements. This hypothesis seems to be confirmed by the 
subjective experience of catatonic patients. Indeed, once remitted from their catatonia, patients 
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report having felt invaded by a major and uncontrollable anxiety. 
Conversely, they do not seem to have been aware of their motor 
state (11). To better understand the brain abnormalities found in 
catatonic patients, it seems essential to focus on the neurological 
mechanisms involved in the physiological integration of emo-
tions. The amygdala appears to have a central role in emotional 
regulation processes, particularly negative emotions, such as fear 
or anxiety (12). The environmental informations are conveyed to 
different brain areas according to each specific sensory modality 
(for example, visual stimuli are conveyed to occipital cortex, audi-
tory informations to temporal cortex, etc.) and secondarily sent 
to the amygdala, serving as an emotional crossroad (12). To start 
making the link amygdala/emotions/catatonia, it may already be 
interesting to note that, in animals, hyperactivation of the amyg-
dala is responsible of a freezing behavior, which is similar to TI 
and symptoms found in the akinetic forms of catatonia (13). Once 
informations are integrated in the amygdala, they may, depend-
ing on the emotional valence, activate different neural circuits. In 
particular, functional MRI studies found that negative emotions 
are associated with increased activation of the orbitofrontal 
cortex (OFC) and the ventromedial prefrontal cortex (VMPFC) 
and decreased activity of dorsolateral prefrontal cortex (DLPFC). 
The exact opposite activation profile occurs with positive emo-
tions making the PFC a regulating crossroad depending on the 
emotion type (14). These variations in the activation/deactivation 
pattern seem to be modulated by the GABAergic system (15).
Each of the involved brain areas is associated with specific func-
tions. OFC is involved in decoding the emotional environmental 
situations and in taking decisions depending on the context (16). 
VMPFC is considered as a self-centered emotional integration 
center. It will allow, in some way, perceiving emotions (17). 
Regarding DLPFC role, it is implicated in cognitive processes 
and action planification (18). It will allow a cognitive approach in 
understanding emotions and a negative feedback on emotional 
processes, especially amygdalian ones. In other words, DLPFC 
performs cognitive control of emotions (19, 20). Furthermore, 
the DLPFC is a major integrative crossroad. Indeed, it receives 
informations, among others, from the posterior parietal cortex, 
which is itself involved in negative emotions (21). DLPFC will 
then project mainly on motor areas (22). It is therefore considered 
as a sensorimotor associative region bridging the gap between 
emotional cognitive perception and motor skills (23).
pATHOpHYSiOLOGY OF CATATOniA
To confirm TI hypothesis in catatonia, functional MRI studies 
have investigated catatonic brain activation during emotional 
processing. One of them compared patients who remitted from 
catatonia to non-catatonic psychiatric patients and finally to 
healthy subjects. Authors found among remitted catatonic 
patients, a hyperactivation of the OFC and the VMPFCs dur-
ing negative emotions compared to the two other groups (24). 
Furthermore, statistical analysis showed a positive correlation 
between the hyperactivation of the OFC and behavioral/emo-
tional symptoms and between the hyperactivation of VMPFCs 
and motor symptoms (24). The authors also found alterations 
in corticocortical connections between (i) OFC and VMPFC; 
(ii) between VMPFC/DLPFC and motor/premotor cortex (24). 
Another study examined the effect of lorazepam [a benzodiaz-
epine known for its effectiveness in catatonia (25, 26)] on the 
modulation of activation patterns of the PFC during negative 
emotions. A decrease in OFC and VMPC hyperactivation was 
observed with lorazepam in successfully treated catatonic 
patients, leading to a regularization of the OCF activity, compared 
to control (27). It seems that GABA and especially the GABA-A 
receptors may play an important role in the pathophysiology of 
catatonia. One study looked at the density of GABA-A receptors 
as well as changes in cerebral perfusion in catatonic patients 
compared to non-catatonic psychiatric patients and healthy 
subjects. The authors found a decrease of the GABA-A receptors 
density in the DLPFC associated with a decrease of cerebral per-
fusion in prefrontal and posterior parietal cortex (28). Moreover, 
motor and affective symptoms were significantly associated with 
the decreased GABA-A receptors density in the DLPFC (28). 
Involvement of the DLPF in catatonia has also been demon-
strated by indirect evidences, such as the therapeutic efficacy 
of high-frequency transcranial magnetic stimulation applied to 
this area (29, 30). Some authors tried to correlate brain activa-
tion changes with different catatonic symptoms, especially motor 
ones. A controlled study using different motor tasks (idle status, 
self-initiated movements, and movements on request) showed a 
decreased activity of the prefrontal cortex, the parietal cortex, and 
the supplementary motor area in catatonic patients compared 
to controls (31). These changes persisted even after remission. 
Specifically, it seems that it is the latency of late motors poten-
tials at the frontoparietal line that is affected in catatonia with 
GABAergic altered sensitivity compared to control (31). These 
results are in agreement with the fact that catatonic patients may 
successfully initiate movements but present difficulties in termi-
nating them (32, 33). Another study examined cerebral perfusion 
changes in catatonic patients before and after treatment with 
electroconvulsive therapy (ECT) and found increased perfusion 
in the parietal cortex after successful treatment (34). Indeed, it 
appears that the parietal cortex may play an important role in 
motricity as demonstrated by the occurrence of a catatonic state 
in patients with a parietal lesion (35). Considering these studies, 
it seems that different brain areas, in addition to the PFC, are 
involved in the catatonia. Neurocognitive studies showed a selec-
tive deficit in visual–spatial performances in catatonic patients 
compared to controls (36). These results confirmed indirectly 
the role of the posterior parietal cortex dysfunction in catatonia 
as it is broadly implicated in visual–spatial performance (37, 
38). A positive correlation was also found between the activity 
of mirror neurons and echophenomena (echopraxia, echolalia) 
and their disappearance after administration of lorazepam (39). 
Indeed, these echo-phenomena seem to be attributed to the 
disinhibition of the mirror neurons, which would be related to 
a control deficit of the GABAergic system, within the OCF, the 
VMPFC, the DLPFC, and the parietal cortex (40). Moreover, 
glutamate seems to be involved in catatonia as well, particularly 
via the NMDA receptors activity. These assumptions are based 
primarily on the efficacy of NMDA-receptor antagonists, such as 
amantadine in catatonia and also in cases of catatonia related to 
anti-NMDA receptor encephalitis (41–44). Amantadine may act 
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by decreasing cerebral glutamatergic activity creating a relative 
increase in the inhibitory GABAergic activity (45).
COnCLUSiOn AnD pERSpECTiVE
The exact mechanisms underlying the pathophysiology of 
catatonia still remain a mystery. It seems that some people 
are more predisposed than others to develop this syndrome. 
Indeed, most studies agreed on the existence of trait markers, 
especially GABAergic cortical dysregulation, resulting in the 
failure of cognitive control of emotions. When intense emo-
tional changes generated by psychiatric disorders (depression, 
mania, and schizophrenia) are added to these predispositions, 
this would precipitate a state of TI: in other words, catatonia. 
Schematically, in response to negative emotions, the GABAergic 
inhibitory control at the OFC could not take place, leading to 
a deregulation in VMPFC/DLPFC balance, which would then 
prevent cognitive control of negative emotions by the DLPFC. 
In addition, the deficit in DLPFC activation would impair its 
associative function, and particularly its connectivity with the 
parietal cortex and the motor areas leading to the occurrence of 
the motor signs found in akinetic forms of catatonia. There are 
many limits to the studies mentioned above: (i) they included a 
small number of patients, (ii) few of them compared catatonic 
patients to healthy controls or to controls with psychiatric 
disorders, and (iii) clinical heterogeneity of catatonia was not 
taken in consideration in these studies. In the future, it might be 
interesting to develop clinico-morphological correlation studies 
with particular attention to the potential role of the amygdala in 
catatonia. This approach might open the way for new therapeutic 
options targeting the amygdala. For example, oxytocin seems to 
have a direct attenuating effect on reactions of fear and anxiety by 
acting directly on the amygdala (46). Other studies focusing on 
the role of glutamate in catatonia could pave the way for thera-
peutic innovations. For example, it is possible to imagine the use 
of drugs with dual action on both GABAergic and glutamatergic 
systems to treat resistant forms of catatonia. Some drugs having 
such properties are already available, especially acamprosate and 
lamotrigine which possesses this dual receptor profile (47). Rapid 
and accurate diagnosis and treatment of catatonia is crucial in 
clinical practice not only to avoid somatic complications but to 
avoid the development of resistance to treatment as well. Indeed, 
the longer catatonic symptoms last, the more will be the risk of 
developing resistance to treatment (48). Consequently, rapid 
achievement of full remission of catatonic symptoms should be 
an essential goal.
AUTHOR COnTRiBUTiOnS
PE and WC participated both to research and writing of the paper 
in the same way.
ACKnOWLEDGMEnTS
PE and WC report no financial relationships with commercial 
interests.
REFEREnCES
1. Fink M. Rediscovering catatonia: the biography of a treatable syndrome. Acta 
Psychiatr Scand Suppl (2013) 127(441):1–47. doi:10.1111/acps.12038 
2. Francis A. Catatonia: diagnosis, classification, and treatment. Curr Psychiatry 
Rep (2010) 12(3):180–5. doi:10.1007/s11920-010-0113-y 
3. Wilson JE, Niu K, Nicolson SE, Levine SZ, Heckers S. The diagnostic criteria 
and structure of catatonia. Schizophr Res (2015) 164:256–62. doi:10.1016/j.
schres.2014.12.036 
4. Sienaert P, Rooseleer J, De Fruyt J. Measuring catatonia: a systematic 
review of rating scales. J Affect Disord (2011) 135(1–3):1–9. doi:10.1016/j.
jad.2011.02.012 
5. Smith JH, Smith VD, Philbrick KL, Kumar N. Catatonic disorder due to a 
general medical or psychiatric condition. J Neuropsychiatry Clin Neurosci 
(2012) 24(2):198–207. doi:10.1176/appi.neuropsych.11060120 
6. Francis A, Fink M, Appiani F, Bertelsen A, Bolwig TG, Bräunig P, et  al. 
Catatonia in diagnostic and statistical manual of mental disorders, fifth 
edition. J ECT (2010) 26(4):246–7. doi:10.1097/YCT.0b013e3181fe28bd 
7. Fink M, Shorter E, Taylor MA. Catatonia is not schizophrenia: Kraepelin’s error 
and the need to recognize catatonia as an independent syndrome in medical 
nomenclature. Schizophr Bull (2010) 36(2):314–20. doi:10.1093/schbul/sbp059 
8. Rosebush PI, Mazurek MF. Catatonia and its treatment. Schizophr Bull (2010) 
36(2):239–42. doi:10.1093/schbul/sbp141 
9. Wing L, Shah A. Catatonia in autistic spectrum disorders. Br J Psychiatry 
(2000) 176(4):357–62. doi:10.1192/bjp.176.4.357
10. Moskowitz AK. “Scared stiff ”: catatonia as an evolutionary-based fear response. 
Psychol Rev (2004) 111(4):984–1002. doi:10.1037/0033-295X.111.4.984 
11. Northoff G, Krill W, Wenke J, Gille B, Russ M, Eckert J, et al. Major differences 
in subjective experience of akinetic states in catatonic and parkinsonian 
patients. Cogn Neuropsychiatry (1998) 3(3):161–78. 
12. Janak PH, Tye KM. From circuits to behaviour in the amygdala. Nature (2015) 
517(7534):2842–9. doi:10.1038/nature14188 
13. Arruda-Carvalho M, Clem RL. Pathway-selective adjustment of pre-
frontal-amygdala transmission during fear encoding. J Neurosci (2014) 
34(47):15601–9. doi:10.1523/JNEUROSCI.2664-14.2014 
14. Phan KL, Wager T, Taylor SF, Liberzon I. Functional neuroanatomy of 
emotion: a meta-analysis of emotion activation studies in PET and fMRI. 
Neuroimage (2002) 16(2):331–48. doi:10.1006/nimg.2002.1087 
15. Northoff G, Witze T, Richter A, Gessner M, Schlagenhauf F, Fell J, et al. GABA-
ergic modulation of prefrontal spatio-temporal activation pattern during 
emotional processing: a combined fMRI/MEG study with placebo and loraze-
pam. J Cogn Neurosci (2002) 14(3):348–70. doi:10.1162/089892902317361895 
16. Rolls ET. Précis of the brain and emotion. Behav Brain Sci (2000) 23(2):177–91; 
discussion 192–233. 
17. Kuo M-F, Nitsche MA. Exploring prefrontal cortex functions in healthy 
humans by transcranial electrical stimulation. Neurosci Bull (2015) 31(2):198–
206. doi:10.1007/s12264-014-1501-9 
18. Tanji J, Hoshi E. Behavioral planning in the prefrontal cortex. Curr Opin 
Neurobiol (2001) 11(2):164–70. 
19. Mitchell RLC, Phillips LH. The overlapping relationship between emotion per-
ception and theory of mind. Neuropsychologia (2015) 70:1–10. doi:10.1016/j.
neuropsychologia.2015.02.018 
20. Morawetz C, Bode S, Baudewig J, Kirilina E, Heekeren HR. Changes 
in effective connectivity between dorsal and ventral prefrontal regions 
moderate emotion regulation. Cereb Cortex (2015). doi:10.1093/cercor/
bhv005 
21. Hallam GP, Webb TL, Sheeran P, Miles E, Wilkinson ID, Hunter MD, et al. The 
neural correlates of emotion regulation by implementation intentions. PLoS 
One (2015) 10(3):e0119500. doi:10.1371/journal.pone.0119500 
22. Goldman-Rakic PS, Bates JF, Chafee MV. The prefrontal cortex and internally 
generated motor acts. Curr Opin Neurobiol (1992) 2(6):830–5. 
23. Kehrer S, Kraft A, Koch SP, Kathmann N, Irlbacher K, Brandt SA. Timing of 
spatial priming within the fronto-parietal attention network: a TMS study. 
Neuropsychologia (2015) 74:30–6. doi:10.1016/j.neuropsychologia.2014.11.017
December 2015 | Volume 6 | Article 1824
Ellul and Choucha Neurobiology and Pharmacotherapy of Catatonia
Frontiers in Psychiatry | www.frontiersin.org
24. Northoff G, Kötter R, Baumgart F, Danos P, Boeker H, Kaulisch T, et  al. 
Orbitofrontal cortical dysfunction in akinetic catatonia: a functional magnetic 
resonance imaging study during negative emotional stimulation. Schizophr 
Bull (2004) 30(2):405–27. 
25. Sharma CM, Jena S, Sharma D, Agrawal RP. Role of lorazepam chal-
lenge test in childhood catatonia. J Pediatr Neurosci (2014) 9(3):301–3. 
doi:10.4103/1817-1745.147611 
26. Lin C-C, Huang T-L. Lorazepam-diazepam protocol for catatonia in 
schizophrenia: a 21-case analysis. Compr Psychiatry (2013) 54(8):1210–4. 
doi:10.1016/j.comppsych.2013.06.003 
27. Richter A, Grimm S, Northoff G. Lorazepam modulates orbitofrontal signal 
changes during emotional processing in catatonia. Hum Psychopharmacol 
(2010) 25(1):55–62. doi:10.1002/hup.1084 
28. Northoff G, Steinke R, Czcervenka C, Krause R, Ulrich S, Danos P, et  al. 
Decreased density of GABA-A receptors in the left sensorimotor cortex in 
akinetic catatonia: investigation of in vivo benzodiazepine receptor binding. 
 J Neurol Neurosurg Psychiatry (1999) 67(4):445–50. 
29. Trojak B, Meille V, Bonin B, Chauvet-Geliner J-C. Repetitive transcranial 
magnetic stimulation for the treatment of catatonia: an alternative treat-
ment to electroconvulsive therapy? J Neuropsychiatry Clin Neurosci (2014) 
26(2):E42–3. doi:10.1176/appi.neuropsych.13050102
30. Cristancho MA, Cristancho P, O’Reardon JP. Other therapeutic psychiatric 
uses of superficial brain stimulation. Handb Clin Neurol (2013) 116:415–22. 
doi:10.1016/B978-0-444-53497-2.00034-6
31. Northoff G, Pfennig A, Krug M, Danos P, Leschinger A, Schwarz A, et  al. 
Delayed onset of late movement-related cortical potentials and abnormal 
response to lorazepam in catatonia. Schizophr Res (2000) 44(3):193–211. 
32. Northoff G, Wenke J, Krill W, Pflug B. Ball experiments in 32 acute akinetic 
catatonic patients: deficits of internal initiation and generation of movements. 
Mov Disord (1995) 10(5):589–95. 
33. Northoff G. What catatonia can tell us about “top-down modulation”: a 
neuropsychiatric hypothesis. Behav Brain Sci (2002) 25(5):555–77; discussion 
578–604. 
34. Escobar R, Rios A, Montoya ID, Lopera F, Ramos D, Carvajal C, et al. Clinical 
and cerebral blood flow changes in catatonic patients treated with ECT. 
J Psychosom Res (2000) 49(6):423–9.
35. Fukutake T, Hirayama K, Komatsu T. Transient unilateral catalepsy and right 
parietal damage. Jpn J Psychiatry Neurol (1993) 47(3):647–50. 
36. Northoff G, Nagel D, Danos P, Leschinger A, Lerche J, Bogerts B. Impairment 
in visual–spatial function in catatonia: a neuropsychological investigation. 
Schizophr Res (1999) 37(2):133–47. 
37. Swaminathan SK, Freedman DJ. Preferential encoding of visual categories 
in parietal cortex compared with prefrontal cortex. Nat Neurosci (2012) 
15(2):315–20. doi:10.1038/nn.3016 
38. Sprague TC, Ester EF, Serences JT. Reconstructions of information in visual 
spatial working memory degrade with memory load. Curr Biol (2014) 
24(18):2174–80. doi:10.1016/j.cub.2014.07.066 
39. Mehta UM, Basavaraju R, Thirthalli J. Mirror neuron disinhibition may 
be linked with catatonic echo-phenomena: a single case TMS study. Brain 
Stimulat (2013) 6(4):705–7. doi:10.1016/j.brs.2012.12.002 
40. Schulte-Rüther M, Markowitsch HJ, Fink GR, Piefke M. Mirror neuron and 
theory of mind mechanisms involved in face-to-face interactions: a functional 
magnetic resonance imaging approach to empathy. J Cogn Neurosci (2007) 
19(8):1354–72. doi:10.1162/jocn.2007.19.8.1354
41. Ene-Stroescu V, Nguyen T, Waiblinger BE. Excellent response to amantadine 
in a patient with bipolar disorder and catatonia. J Neuropsychiatry Clin 
Neurosci (2014) 26(1):E43. doi:10.1176/appi.neuropsych.13020038 
42. Carroll BT, Goforth HW, Thomas C, Ahuja N, McDaniel WW, Kraus 
MF, et  al. Review of adjunctive glutamate antagonist therapy in the 
treatment of catatonic syndromes. J Neuropsychiatry Clin Neurosci (2007) 
19(4):406–12. doi:10.1176/jnp.2007.19.4.406
43. Lee EM, Kang JK, Oh JS, Kim JS, Shin Y-W, Kim C-Y. 18F-fluorodeoxyglucose 
positron-emission tomography findings with anti-N-methyl-D-aspartate 
receptor encephalitis that showed variable degrees of catatonia: three cases 
report. J Epilepsy Res (2014) 4(2):69–73. 
44. Yoshimura B, Yada Y, Horigome T, Kishi Y. Anti-N-methyl-D-aspartate 
receptor encephalitis presenting with intermittent catatonia. Psychosomatics 
(2014) 56(3):313–5. doi:10.1016/j.psym.2014.06.005 
45. Duncan NW, Wiebking C, Northoff G. Associations of regional GABA and 
glutamate with intrinsic and extrinsic neural activity in humans – a review 
of multimodal imaging studies. Neurosci Biobehav Rev (2014) 47:36–52. 
doi:10.1016/j.neubiorev.2014.07.016 
46. Eckstein M, Becker B, Scheele D, Scholz C, Preckel K, Schlaepfer 
TE, et  al. Oxytocin facilitates the extinction of conditioned fear 
in humans. Biol Psychiatry (2014) 78(3):194–202. doi:10.1016/j.
biopsych.2014.10.015 
47. Kalk NJ, Lingford-Hughes AR. The clinical pharmacology of acamprosate. Br 
J Clin Pharmacol (2014) 77(2):315–23. doi:10.1111/bcp.12070
48. Narayanaswamy JC, Tibrewal P, Zutshi A, Srinivasaraju R, Math SB. Clinical 
predictors of response to treatment in catatonia. Gen Hosp Psychiatry (2012) 
34(3):312–6. doi:10.1016/j.genhosppsych.2012.01.011 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2015 Ellul and Choucha. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License (CC BY). The 
use, distribution or reproduction in other forums is permitted, provided the 
original author(s) or licensor are credited and that the original publication in 
this journal is cited, in accordance with accepted academic practice. No use, 
distribution or reproduction is permitted which does not comply with these 
terms.
